A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme

Trial Profile

A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Follitropin delta (Primary) ; Follitropin alfa
  • Indications Female infertility
  • Focus Pharmacodynamics; Registrational
  • Acronyms ESTHER-2
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
    • 20 Jan 2017 This trial was completed in Belgium, European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top